|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Vertigo | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Cerebral Infarction | |||||
| Infarction | |||||
| Stroke | |||||
| 3 | More general conditions related to this trial | ||||
| Brain Diseases | |||||
| Brain Infarction | |||||
| Brain Ischemia | |||||
| Cardiovascular Diseases | |||||
| Central Nervous System Diseases | |||||
| Cerebrovascular Disorders | |||||
| Ear Diseases | |||||
| Ischemia | |||||
| Labyrinth Diseases | |||||
| Necrosis | |||||
| Nervous System Diseases | |||||
| Neurologic Manifestations | |||||
| Otorhinolaryngologic Diseases | |||||
| Pathologic Processes | |||||
| Signs and Symptoms | |||||
| Vascular Diseases | |||||
| Vestibular Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Merislon | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Betahistine | |||||
| 6 | More general drug interventions related to this trial | ||||
| Cardiovascular Agents | |||||
| Histamine Agents | |||||
| Histamine Agonists | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| Vasodilator Agents | |||||
| 7 | Sponsors listed in this trial | ||||
| Eisai China Inc. | |||||